Posted by Michael Wonder on 09 Apr 2019
FDA approves new treatment for osteoporosis in post-menopausal women at high risk of fracture
9 April 2019 - The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).
These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
The safety and efficacy of Evenity were demonstrated in two clinical trials involving a total of more than 11,000 women with post-menopausal osteoporosis.
